Lipella Pharmaceuticals Inc. has been delisted from Nasdaq due to non-compliance with certain listing rules related to private placement transactions completed between December 2024 and March 2025. This delisting was not a result of financial instability but rather due to issues with the issuance of voting convertible preferred stock and warrants. As of June 19, 2025, Lipella's shares are now traded on the OTC Pink Market under the symbol LIPO. The company is actively exploring options to relist on a national exchange and plans to submit an initial listing application soon. Additionally, Lipella expects to report final topline data from the fully enrolled Phase 2a trial of LP-310 in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.